Biocon Biologics' drug substance facility in Bengaluru has been classified by the USFDA as voluntary action indicated after a cGMP inspection conducted in February 2024. The classification means that while some objections were noted, no regulatory action is recommended. The facility is responsible for supplying rh-Insulin drug substance to the US.
